CDC25A phosphatase activates multiple cyclin-dependent kinases (CDK) during cell cycle progression. Inactivation of CDC25A by ubiquitin-mediated degradation is a major mechanism of DNA damage-induced S-G 2 checkpoint.
Introduction
Cyclin-dependent kinases (CDK) play central roles in promoting progression of the cell cycle in all eukaryotic cells (1) . CDK activity undergoes multiple layers of regulatory processes, including association with cyclins and inhibitors and post-translational modifications of CDK proteins, such as phosphorylation and dephosphorylation. Although phosphorylation of the T loop, e.g., Thr 161 of CDK1, is required for full activation of CDKs, phosphorylation around the ATP binding site, e.g., Tyr 15 of CDK1, is inhibitory on the CDK activity. The inhibitory phosphorylation of CDKs is mediated by Wee1 or Myt1 kinases, and dephosphorylation of the sites is catalyzed by CDC25 family phosphatases (2) . This inhibitory phosphorylation plays important roles in controlling the timing of CDK activation. CDK2 activated by association with cyclin E and cyclin A governs initiation and completion of DNA replication. CDC25A-mediated dephosphorylation of CDK2 is critical for appropriate progression of S phase. CDK1 activated by cyclin A and cyclin B plays an essential role in initiation and completion of mitosis. All CDC25 phosphatases, i.e., CDC25A, CDC25B, and CDC25C, are likely to collaborate in timely activation of CDK1-cyclin A and CDK1-cyclin B during G 2 -M transition. However, cells with compound disruption of CDC25B and CDC25C display minimum change in cell cycle progression (3) . In contrast, CDC25A may play a nonredundant role in CDK1 activation (4) . Knockdown of CDC25A by RNA interference delays both G 1 -S and G 2 -M transitions (5) , whereas overexpression of CDC25A can induce aberrant mitotic events (6) .
Inactivation of CDC25 phosphatases is a major mechanism of cell cycle checkpoint (2) . In response to DNA damage, activated CHK1 and CHK2 phosphorylate CDC25A and CDC25C (7, 8) . It has been shown that CHK2-mediated phosphorylation inactivates CDC25C by cytoplasmic sequestration (7) . On the other hand, CHK1-mediated CDC25A phosphorylation results in ubiquitination by the Skp1-Cullin-h-TrCP E3 complex and rapid proteasome-dependent degradation (9, 10) . The CHK1-mediated CDC25A degradation leads to cell cycle arrest in S or G 2 phase. This is an acute response to DNA damage without employing new transcription or translation, in contrast to p53-dependent checkpoint responses involving transcription of p21 Cip1 (11) and 14-3-3j (12, 13) . CHK1 predominantly regulates cellular levels of CDC25A protein even during unperturbed cell cycle progression. Deregulation of checkpoint pathways is thought to play a key role in tumor progression. For instance, loss of the proximal checkpoint kinase ATM, which functions upstream of CHK1/2, strongly predisposes humans and mice to tumorigenesis (14, 15) . Haploinsufficiency of another proximal kinase, ATR, promotes tumorigenesis in mice with defective DNA-mismatch repair (16) . Furthermore, Chk1 heterozygous mice exhibit enhanced tumorigenesis induced by Wnt-1 (17) . Consistently with the notion that CDC25A is a major target of the Chk1 pathway, cellular CDC25A levels are increased in Chk1-heterozygous mice (18) . CDC25A expression is significantly increased in a variety of human cancers, including head and neck, liver, thyroid, breast, ovary, and lung cancers (19) (20) (21) (22) (23) (24) (25) . These observations suggest that tumor-suppressive action of the checkpoint pathway may depend largely on control of CDC25A expression within proper levels. In the present study, we examined whether CDC25A is rate limiting for cellular transformation and in vivo tumorigenesis using a newly generated Cdc25A-null mouse line.
Materials and Methods
Generation of mouse lines. Cdc25A mutant mouse lines were generated by gene targeting in a 129/sv mouse embryonic stem (ES) cell line, GS-1, followed by injection into C57BL/6 mouse embryos at the blastocyst stage, as previously described (26) . Chimeras were then crossbred with wild-type C57BL/6 mice to generate germ line heterozygous mutants. Two ES clones, 2G6 and 2E11, went germ line, and homozygotes from both clones exhibited similar embryonic lethal phenotype. Therefore, mice from 2G6 were further characterized for this study. MMTV-H-ras, MMTV-neu, and MMTV-myc mice were described previously (27, 28) . Mice were maintained according to protocols approved by the Institutional Animal Care Committees at Northwestern University and University of Illinois according to the AAALAS regulation. The primers used for genotyping PCR are SW39, 5 ¶-ATATTGCT-GAAGAGCTTGGCGG-3 ¶, HK507, 5 ¶-CTTCTGTTACTGTGTGTAG-GATTGTTG-3 ¶; and HK521, 5 ¶-CTTTCTAGTGATCGGATGGTATATGGA-3 ¶. The annealing temperature used for the 35-cycle PCR reaction was 62jC. To detect tumorigenesis, each mouse was physically examined twice a week, and the date of detecting palpable tumors was recorded. Mice were sacrificed when diameters of primary tumors reached 2 cm. For immunohistochemical analysis of proliferating cells, mice were injected i.p. with bromodeoxyuridine (BrdUrd, 50 Ag/g body weight) at 2 h before sacrifice.
Cell cultures. Mouse embryonic fibroblasts (MEF) were isolated from day 12.5 mouse embryos and cultured as previously described (29) . To determine cumulative population doublings, MEFs were cultured according to a 3T3 protocol, inoculated at the density of 3 Â 10 5 per 25-cm 2 area (60-mm dish), and subcultured every 3 days. The population doubling level during each passage was calculated according to the formula: log( final cell number/3 Â 10 5 )/log 2. MCF-10A cells were cultured in DMEM/F12 supplemented with 5% heat-inactivated horse serum, 10 Ag/mL insulin, 0.5 Ag/mL hydrocortisone, 20 ng/mL recombinant human epithelial growth factor, 2 mmol/L L-glutamine, and 100 Ag/mL penicillin/streptomycin. The sequences of small interfering RNAs (siRNA) 1 and 3 for targeting human CDC25A mRNA were 5 ¶-AGCAACCACUGGAGGUGAAG-3 (residues 179-198) and 5 ¶-AACCUUGACAACCGAUGCA-3 ¶ (residues 751-769), respectively. Recombinant lentiviruses for expression of the siRNAs as short hairpin loops were constructed using the BLOCK-iT Lentiviral RNAi Expression System (Invitrogen) according to the manufacturer's instructions. Infected cells were selected with 10 Ag/mL blasticidin. Retrovirus transduction of H-ras V12 plus DNp53 and soft-agar colony formation assays were done as previously described (30) . Cell cycle analysis for serumstimulated MEFs was done as previously described (29) .
Immunologic analyses. For immunoblotting and immunoprecipitation, cells on culture dishes were scraped into lysis buffer and then sonicated as described previously (29) . Anti-CDC25A monoclonal antibody (clone Ab3) was obtained from Neomarkers. Anti-BrdUrd monoclonal antibody was purchased from DAKO Inc. Phosphospecific anti-CDK1/2 rabbit polyclonal antibody was obtained from Calbiochem. Anti-CDK1 and CDK2 antibodies were purchased from Santa Cruz Biotechnology, and monoclonal h-actin (AC-15) antibody was from Sigma. The terminal nucleotidyl transferasemediated nick end labeling (TUNEL) in situ hybridization kit was purchased from Oncor. Percentages of apoptotic cells and S-phase cells were determined by counting TUNEL-and BrdUrd-positive cells, respectively. Three animals per genotype were analyzed, and at least 600 epithelial cells per stained section were scored for quantification.
Checkpoint analysis. G 2 checkpoint was analyzed as described previously (5) . Briefly, cells were mock irradiated or irradiated by 0.2-1.5 Gy IR from a 60 Co source. After 30 min incubation, cells were then treated with 100 ng/mL nocodazole to block mitotic progression of cells that did not arrest at G 2 . Two hours later, cells were fixed and stained with propidium iodide and the phospho-histone H3 antibody (Upstate Biotechnology). Samples were then analyzed by flow-cytometric analyses using a Becton Dickinson FACScan, as described previously (31) .
Mammary gland whole mount. Inguinal mammary glands were dissected, spread onto glass slide, fixed in 10% buffered formalin, hydrated, stained overnight in 0.2% carmine (Sigma) and 0.5% AlK(SO 4 ) 2 , dehydrated in graded solutions of ethanol, and cleared in Histoclear (National Diagnostics). Tissues were examined under an inverted microscope and photographed.
Statistical analyses. Kaplan-Meier tumor-free survival curves were compared between strains by the log-rank test analysis, and P values were determined. The significance did not change when the Wilcoxon test was used instead. Other statistical analyses were done using ANOVA and Student's t test.
Results
Hemizygous disruption of Cdc25A results in modestly enhanced G 2 checkpoint and shortened proliferative life span. To determine the roles of CDC25A in development and oncogenesis, we generated a Cdc25A-deficient mouse line by standard gene targeting in embryonic stem cells ( Fig. 1A and B). Exons 7 to 9 were replaced with a neomycin-resistant gene cassette. Intercross breeding of germ line heterozygous mice displayed that all homozygous mice died in utero. Histologic examinations of embryos revealed that homozygous mutants die at embryonic day 5 to 7 (E5-7), and homozygous blastocysts (E3.5 embryos) showed impaired hatching in vitro. This embryonic lethal phenotype of Cdc25A-null mice is being further characterized and will be reported elsewhere. Cdc25A-heterozygous (Cdc25A +/À ) mice seemed healthy and showed normal fertility and mammary function. For ex vivo studies, we prepared Cdc25A +/À and wildtype (Cdc25A +/+ ) MEFs. Because of the early lethality, we were unable to isolate cells from Cdc25A À/À embryos. Immunoblotting showed that levels of CDC25A protein in Cdc25A +/À MEFs were about 40% lower than those in Cdc25A +/+ MEFs (Fig. 1C) . Immunoblotting with an antibody specific for CDK1/2 phosphorylated on Tyr 15 showed that Tyr 15 phosphorylation on these CDK proteins was increased by 1.6-fold in Cdc25A +/À MEFs. Immunoprecipitation of CDK1 or CDK2 followed by immunoblotting with the Tyr 15 phosphospecific antibody further showed that tyrosine phosphorylation on both CDK1 and CDK2 was enhanced. These observations are consistent with the notion that CDC25A mediates tyrosine dephosphorylation of CDK1 and CDK2. Cdc25A +/À and Cdc25A +/+ MEFs at early passages showed similar proliferation rates ( Fig. 2A) despite the changes in CDC25A levels and CDK1/2 phosphorylation. Cdc25A +/À MEFs also exhibited normal kinetics of cell cycle entry from quiescence in response to serum stimulation (Fig. 2B, Supplementary Fig. S1 ). To further examine the replicative capacity of cells with hemizygous Cdc25A disruption, Cdc25A
+/À and Cdc25A +/+ MEFs were continuously cultured according to a 3T3 protocol (Fig. 2C) . Cdc25A +/À and Cdc25A
MEFs exhibited comparable population doublings up to passage 8. Cdc25A +/+ MEFs ceased proliferation by passages 14 to 16. Cdc25A +/À MEFs slowed down proliferation significantly earlier, displaying typical senescent morphology by passages 9 and 10. These observations suggest that hemizygous loss of Cdc25A shortens proliferative life span of primary fibroblasts. We then examined G 2 checkpoint response of Cdc25A +/À and Cdc25A
MEFs to DNA damage (Fig. 2D ) using an experimental scheme previously applied for the characterization of Cdc25B and Cdc25C knock-out MEFs (5). MEFs were treated with increasing doses of ionizing irradiation (IR), and then the ability of G 2 cells to enter into mitosis within 2 h after IR was monitored. At 30 min after IR, nocodazole was added into culture media to block cells at the prometaphase. At 120 min after IR, percentages of mitotic cells were determined by flow cytometry. IR decreased progression of G 2 cells into mitosis, and the decrease was more remarkable in Cdc25A +/À cultures, relative to that in Cdc25A +/+ cultures. Levels of CDC25B or CDC25C were not significantly different between Cdc25A +/À and Cdc25A +/+ MEFs (data not shown). In contrast to the effect on G 2 checkpoint, Cdc25A heterozygosity minimally affected G 1 checkpoint, when Cdc25A +/À MEFs synchronized by serum starvation were treated with IR and restimulated with serum ( Supplementary Fig. S2 ). No significant differences in DNA synthesis were observed in exponentially proliferating Cdc25A +/À and Cdc25A +/+ MEFs exposed to IR, suggesting no major change in intra-S checkpoint (data not shown). These results suggest that Cdc25A +/À cells have modestly enhanced G 2 checkpoint and shortened proliferating life span, whereas unperturbed cell cycle progression during early passages is essentially unaltered.
Heterozygous disruption of CDC25A inhibits cellular transformation. To assess cellular potential to undergo transformation, (Fig. 3A) . Decreased susceptibility of Cdc25A +/À MEFs to transformation induced by H-ras V12 + DNp53 was also confirmed by focus formation assays in monolayer cultures (data not shown). These observations suggest that the cellular level of CDC25A is part of a rate-limiting mechanism of malignant transformation. To further delineate the role of CDC25A in transformation, we examined the effect of CDC25A knockdown in nontransformed human mammary epithelial MCF-10A cells. Two recombinant lentiviruses encoding different short hairpin RNAs, CDC25A shRNA 1 and 3, were used to knockdown CDC25A in MCF-10A cells. Lentiviral expression of shRNA 1 and 3 resulted in 57% and 35% Figure 3 . Cellular CDC25A levels play a rate-limiting role in ras -mediated transformation. A, transformation assays by scoring colony formation in soft agar following retroviral transduction of H-ras V12 and a dominant negative (DN ) p53 mutant. Numbers of transformed colonies per plate scored on day 17 after plating are indicated as means + SE from three independent cell preparations per genotype. The difference is statistically significant (P = 0.0086). B, immunoblotting for CDC25A in human mammary epithelial MCF-10A cells expressing anti-CDC25A short hairpin RNA (shRNA 1 and 3) or control nonspecific (NS ) double-stranded RNA. C, soft agar colony formation assay using MCF-10A cells with decreased CDC25A expression. Following the lentiviral shRNA transduction, cells were infected with retrovirus encoding H-ras V12 and a dominant negative p53 mutant. Cells were then plated in soft agar, and colony formation was scored. D, the numbers of colonies in soft agar per plate was scored on day 17 after plating and are shown as means + SE from three independent experiments. P = 0.038 and 0.069 for control versus Cdc25A shRNA 1 and 3, respectively. decreases in cellular Cdc25A levels, respectively (Fig. 3B) . These shRNAs did not significantly affect cellular levels of CDC25B or CDC25C and minimally affected the rate of proliferation (data not shown). To determine effects of CDC25A knockdown on transformation, at 24 h post-lentiviral infection, cells were infected with the H-ras V12 + DNp53 retrovirus. The expression of shRNA 1 and 3 decreased the numbers of transformed colonies by 58% and 36%, respectively, compared with control expression of nonspecific shRNA ( Fig. 3C and D) . When the shRNA lentiviruses were infected at 24 h after retroviral transduction of H-ras V12 + DNp53, we did not observe any significant difference in colony formation between the control and anti-CDC25A shRNAs (data not shown). These data suggest that cellular CDC25A levels at the time of oncogene activation are critical and indicate that CDC25A plays a ratelimiting role in ras-mediated transformation.
Hemizygous loss of Cdc25A delays H-ras-or neu-induced mammary tumorigenesis. Cdc25A +/À mice exhibited normal development of all examined tissues, including mammary glands (Supplementary Fig. S3 ). We then addressed the question whether Cdc25A heterozygosity inhibits in vivo tumorigenesis, by crossbreeding Cdc25A +/À mice with MMTV-H-ras or MMTV-neu transgenic mice, which are well-established models for spontaneous mammary tumorigenesis (27, 28) . Cdc25A +/+ ;MMTV-H-ras mice developed mammary and salivary tumors with average latency of 18 weeks (Fig. 4A) . In striking contrast, the tumor latency of Cdc25A +/À ;MMTV-H-ras mice was 60 weeks, demonstrating a marked delay in tumorigenesis. It is noteworthy that about 10% of Cdc25A +/À ;MMTV-H-Ras mice did not develop detectable tumors over 2 years of monitoring. Cdc25A +/À ;MMTV-neu mice also exhibited significantly delayed tumorigenesis, with median latency of 32 weeks, relative to the latency of 23 weeks in Cdc25A +/+ ;MMTV-neu mice (Fig. 4B) . Thus, hemizygous loss of Cdc25A delays or inhibits ras-and neu-induced tumorigenesis. The macro-and microscopic morphologic characteristics and growth rates were indistinguishable between palpable (>0.5 cm) mammary adenocarcinomas induced by H-ras or neu in the Cdc25A +/+ background and in Cdc25A +/À background (data not shown). To further characterize early events before tumor detection, we did whole-mount analyses of mammary tissues in virgin mice. Mammary glands from 12-week-old Cdc25A +/+ ;MMTVneu mice showed proliferative disturbances as evidenced by hyperplastic nodules (Fig. 5A) , which is in concordance with previous reports (28) . Mammary glands from Cdc25A +/À ;MMTVneu mice exhibited grossly normal postnatal development of mammary epithelia, and focal proliferative lesions were less obvious. For a clue to the mechanism of the early changes rendered by Cdc25A heterozygosity, we then analyzed apoptosis and proliferation in mammary tissues from 5-week-old Cdc25A +/À ; MMTV-neu and Cdc25A +/+ ;MMTV-neu mice (Fig. 5B) . TUNEL analysis showed that there was no significant difference in apoptosis between the two groups. In contrast, percentages of S-phase cells, determined by BrdUrd immunohistochemistry, in mammary epithelia of Cdc25A +/À ;MMTV-neu mice were significantly lower than those of Cdc25A +/+ ;MMTV-neu mice (8.65 F 1.49% versus 26.4 F 5.74%). Decreased proliferation in Cdc25A +/À ; MMTV-neu mammary epithelia was correlated with increased immunoreactivities to the antibody specific to Tyr 15 -phosphorylated CDK1/2. These data suggest that hemizygous loss of CDC25A is inhibitory on tumor initiation, mostly by down-regulation of proliferation stimulated by the neu-ras oncogenic pathway. The cell proliferation in mammary epithelia was almost comparable between Cdc25A +/+ and Cdc25A +/À mice without MMTV-neu (7.47 F 1.99% versus 6.85 F 1.49%; Fig. 5C , Supplementary  Fig. S4 ). These data clearly suggest that the cellular level of Cdc25A is critical for oncogene-induced cell proliferation. +/À mice expressing MMTV-neu oncogene display hypoproliferation with increased tyrosine phosphorylation of CDK proteins. A, whole-mount analysis of mammary glands from 12-wk-old mice with the indicated genotypes. B, TUNEL assay and immunohistologic analyses for BrdUrd incorporation and Tyr 15 phosphorylation of CDK1/2 in mammary tissues of 5-wk-old mice. Mice with the indicated genotypes were administered i.p. with BrdUrd, and 2 h later, mammary tissues were sampled. C, the percentage of BrdUrd-positive cells in mammary epithelia of 5-week-old Cdc25A +/+ and Cdc25A +/À mice in the presence and absence of neu oncogene are shown as a means + SE. *, P = 0.008; **, P = 0.007, statistically significant differences. The difference between Cdc25A +/À mice and Cdc25A +/À ; MMTV-neu mice was not statistically significant (P = 0.315). Finally, we examined the effect of Cdc25A heterozygosity on tumorigenesis initiated by another oncogenic signal, c-myc overexpression. Cdc25A +/À mice were crossbred with MMTV-myc transgenic mice, which is also a widely used murine mammary tumor model (27) . In contrast to ras-and neu-induced tumorigenesis, the median tumor latency in Cdc25A +/À ;MMTV-myc mice was not statistically different from that in Cdc25A +/+ ;MMTV-myc mice (44 weeks versus 40 weeks; Fig. 4C ). Taken together, these in vivo effects of hemizygous CDC25A disruption suggest that cellular levels of CDC25A form a critical factor determining the efficacy of tumorigenesis initiated specifically by activation of the neu-ras oncogenic pathway.
Discussion
CDC25A activates multiple cyclin/CDK complexes throughout the cell cycle (5). The present study has shown that hemizygous disruption of the Cdc25A gene results in inhibition of ras-mediated transformation, although continuous cell cycle progression and serum-induced cell cycle entry are minimally affected. These observations suggest that the cellular level of CDC25A is rate limiting for malignant transformation that involves oncogenic action of ras. Consistently, tumorigenesis induced by the MMTV-Hras or neu transgene is substantially delayed in Cdc25A +/À mice. The data showing that f50% reduction in CDC25A expression is sufficient to inhibit tumor initiation indicate a critical role for CDC25A phosphatase in HER2/neu-ras-mediated mammary tumorigenesis. Cdc25A heterozygosity inhibits ras-induced tumorigenesis most remarkably and influences neu-induced tumorigenesis to a lesser extent. This difference implies that CDC25A activation is involved specifically in the ras-mitogen-activated protein kinase pathway, whereas other downstream targets of the Her2/neu oncogenic signal, e.g., the phosphoinositide-3-kinase-Akt pathway, may not depend on CDC25A. In contrast, Cdc25A heterozygosity had no significant effect on myc-induced tumorigenesis. These differential effects of the Cdc25A +/À background are reminiscent of those of cyclin D1 or Pin1 ablation. Both cyclin D1-null (Ccnd1 À/À ) mice and Pin1-null (Pin1 À/À ) mice are refractory to MMTV-neu-and MMTV-H-ras-induced tumorigenesis, whereas they are sensitive to MMTV-myc-induced tumorigenesis (32, 33) . Pin1 seems to function upstream of cyclin D1 in mammary tumorigenesis (33) . The detail of the interplay of CDC25A and cyclin D1 in the neu-ras oncogenic pathway is yet to be elucidated. The major substrates of CDC25A are thought to be CDK1 and CDK2, and it remains unclear whether CDC25A activates cyclin D-CDK4(CDK6) complex during normal cell cycle progression or oncogenic transformation. Because CDC25A is an E2F target gene (34) , cyclin D1 overexpression may result in the up-regulation of CDC25A via E2F activation. The unaltered sensitivity of Cdc25A +/À mice to myc-induced tumorigenesis implies that CDC25A does not play a key role in the oncogenic action of myc despite a previous report that CDC25A is a myc-target gene (35) . It is possible that like Wnt-1, myc overexpression may induce oncogenesis in stem cells or very early progenitor cells in the mammary tissue. On the other hand, activation of the neu-ras pathway might transform more differentiated mammary epithelial cells, depending on cyclin D1 and CDC25A activation. Further investigations are necessary to fully understand the specificity of oncogenic pathways that require CDC25A function.
The present study, as well as previous studies using knock-out mice, suggests diverse functions of the CDC25 family proteins.
Cdc25A
À/À mice are lethal during the peri-implantation period.
+/À MEFs proliferate normally during early passages, but display modestly enhanced G 2 checkpoint response to DNA damage and markedly decreased efficiency in ras-mediated transformation. Cdc25A +/À MEFs also undergo senescence at earlier passages than wild-type MEFs do. Decreased sensitivity of Cdc25A +/À MEFs to transforming signals could be associated with premature senescence, according to the recent notion that senescence induced by oncogenic or oxidative stress is a potent barrier against malignant transformation (36) . On the other hand, no substantial effects of Cdc25A heterozygosity on apoptosis were observed when MEFs were exposed to IR or serum starved (data not shown). Consistently, in mammary tissues of Cdc25A +/À ;MMTV-neu mice before tumor development, we observed decreased proliferation with increased Tyr 15 phosphorylation, but no robust change in apoptosis. Thus, cells with reduced CDC25A expression seem to have impaired proliferative capacity in response to oncogenic stimuli or stress, whereas apoptotic responses seem to be unaltered. The inhibitory effect on proliferative capacity may account for the relative resistance of Cdc25A +/À mice to neu/ras-induced mammary tumorigenesis. Although CDC25A overexpression could affect apoptotic responses (37) , the present study shows that hemizygous loss of CDC25A does not have major impacts on apoptotic control. In contrast with the phenotypes of Cdc25A knock-out mice, Cdc25B-null mice develop normally except for a meiotic defect during oogenesis (38) . Cdc25C-null mice seem healthy (39) . Interestingly, Cdc25B À/À MEFs and Cdc25C À/À MEFs exhibit no change in cell cycle progression or checkpoint function. Therefore, CDC25A plays a nonredundant role in embryogenesis and oncogenesis, whereas CDC25B and CDC25C are essentially dispensable. Although transgenic mice expressing CDC25B under the MMTV promoter display precocious alveolar hyperplasia (40) and modestly increased susceptibility to a carcinogen (41) , it remains obscure whether CDC25B or CDC25C plays a ratelimiting role in oncogenesis. Taken together, among the CDC25 family, CDC25A is highlighted as an indispensable regulator of developmental and oncogenic proliferation. Delayed tumorigenesis in the Cdc25A +/À background not only indicates the importance of CDC25A in tumor initiation, but also presents a scientific foundation for CDC25A as a potent therapeutic target. A clinical study reported that f50% of T 1a,b breast cancer tissues exhibited CDC25A overexpression, which correlated with poor survival (25) . Our recent study showed that ectopic expression of CDC25A by an MMTV-CDC25A transgene significantly accelerates development of mammary tumors in MMTV-H-ras or MMTV-neu mice (42) . Tumors with the MMTV-CDC25A transgene exhibit markedly accelerated growth and more invasive characteristics with chromosomal instability, which are consistent with the suggested role for CDC25A in malignant phenotypes of human breast cancer. Furthermore, the inhibitory effect of the Cdc25a +/À background on the ras-neu oncogenic pathway supports the rationale of using CDC25A inhibitors for therapeutic intervention. Multiple small-molecule agents including vitamin K analogues have been developed as pharmacologic inhibitors of CDC25 phosphatases (43) (44) (45) . One of such CDC25 inhibitors, BN82685, exhibits in vivo tumor inhibitory activity as an orally bioactive agent (46) . Further investigations are needed to establish chemotherapeutic strategies targeted on CDC25 phosphatases, especially for breast cancer with Her2/neu overexpression. The mouse models with altered CDC25A levels will be useful tools for examining biological impacts of CDC25-targeted therapeutic intervention.
